Landos Biopharma Inc. (LABP)
NASDAQ: LABP
· Real-Time Price · USD
22.93
0.13 (0.57%)
At close: May 23, 2024, 8:00 PM
0.57% (1D)
| Bid | 22.47 |
| Market Cap | 71.68M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.8M |
| EPS (ttm) | -4 |
| PE Ratio (ttm) | -5.7325 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 24.51 |
| Volume | 50,899 |
| Avg. Volume (20D) | 27,036 |
| Open | 22.93 |
| Previous Close | 22.80 |
| Day's Range | 22.75 - 22.94 |
| 52-Week Range | 3.15 - 22.94 |
| Beta | 0.14 |
About LABP
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted ora...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 2021
Employees 19
Stock Exchange NASDAQ
Ticker Symbol LABP
Website https://landosbiopharma.com